All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During the 2022 ASCO Annual Meeting, the AML Hub spoke with Courtney DiNardo, MD Anderson Cancer Center, Houston, US. We asked, What factors affect how a patient responds to ivosidenib treatment?
What factors affect how a patient responds to ivosidenib treatment?
DiNardo begins by outlining important factors when using ivosidenib in the single-agent relapse setting and the new information we have learned from the AGILE trials, which combined ivosidenib with azacitidine. DiNardo notes that, although patients with complex cytogenetics appeared to have less benefit, more data is needed to draw conclusions.
1st NCRI AML academy meeting | What is the optimum treatment strategy for elderly or frail patients with AML?
Prof Courtney DiNardo spoke to us at the 1st NCRI AML academy meeting on the topic of the optimum strategy for the treatment of elderly or...
Assist. Prof. Courtney DiNardo | ASH 2017 | Ivosidenib in IDH1 AML
Assist. Prof. Courtney DiNardo | ASH 2017 | Ivosidenib in IDH1 AML 59th ASH annual ASH Meeting and Exposition, 9 - 12 Dec 2017, Atlanta, GA
Subscribe to get the best content related to AML delivered to your inbox